Is COMPASS Pathways (NASDAQ:CMPS) Using Debt Sensibly?

NasdaqGS:CMPS 1 Year Share Price vs Fair Value
NasdaqGS:CMPS 1 Year Share Price vs Fair Value
Explore COMPASS Pathways's Fair Values from the Community and select yours

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We can see that COMPASS Pathways plc (NASDAQ:CMPS) does use debt in its business. But should shareholders be worried about its use of debt?

Advertisement

When Is Debt A Problem?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. When we think about a company's use of debt, we first look at cash and debt together.

What Is COMPASS Pathways's Net Debt?

As you can see below, at the end of June 2025, COMPASS Pathways had US$30.9m of debt, up from US$29.4m a year ago. Click the image for more detail. However, it does have US$221.9m in cash offsetting this, leading to net cash of US$190.9m.

debt-equity-history-analysis
NasdaqGS:CMPS Debt to Equity History August 7th 2025

A Look At COMPASS Pathways' Liabilities

We can see from the most recent balance sheet that COMPASS Pathways had liabilities of US$31.3m falling due within a year, and liabilities of US$99.7m due beyond that. Offsetting this, it had US$221.9m in cash and US$37.3m in receivables that were due within 12 months. So it can boast US$128.2m more liquid assets than total liabilities.

It's good to see that COMPASS Pathways has plenty of liquidity on its balance sheet, suggesting conservative management of liabilities. Because it has plenty of assets, it is unlikely to have trouble with its lenders. Simply put, the fact that COMPASS Pathways has more cash than debt is arguably a good indication that it can manage its debt safely. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine COMPASS Pathways's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

Check out our latest analysis for COMPASS Pathways

Given its lack of meaningful operating revenue, COMPASS Pathways shareholders no doubt hope it can fund itself until it has a profitable product.

So How Risky Is COMPASS Pathways?

We have no doubt that loss making companies are, in general, riskier than profitable ones. And the fact is that over the last twelve months COMPASS Pathways lost money at the earnings before interest and tax (EBIT) line. And over the same period it saw negative free cash outflow of US$148m and booked a US$138m accounting loss. However, it has net cash of US$190.9m, so it has a bit of time before it will need more capital. Overall, its balance sheet doesn't seem overly risky, at the moment, but we're always cautious until we see the positive free cash flow. The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately, every company can contain risks that exist outside of the balance sheet. Case in point: We've spotted 4 warning signs for COMPASS Pathways you should be aware of, and 3 of them are a bit concerning.

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:CMPS

COMPASS Pathways

Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.

Moderate risk and slightly overvalued.

Advertisement

Weekly Picks

ST
stuart_roberts
UG logo
stuart_roberts on Upside Gold ·

An Undervalued 3.3Moz Gold Project in Canada

Fair Value:CA$5.0768.4% undervalued
283 users have followed this narrative
1 users have commented on this narrative
40 users have liked this narrative
GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8590.6% undervalued
89 users have followed this narrative
1 users have commented on this narrative
23 users have liked this narrative
TO
Tokyo
ABI logo
Tokyo on Anheuser-Busch InBev ·

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire

Fair Value:€89.4521.3% undervalued
7 users have followed this narrative
3 users have commented on this narrative
3 users have liked this narrative
OS
oscargarcia
AMZN logo
oscargarcia on Amazon.com ·

The capitalist colossus that makes your parcels magically appear, powers half the internet, and knows your shopping habits.

Fair Value:US$2801.8% undervalued
61 users have followed this narrative
1 users have commented on this narrative
2 users have liked this narrative

Updated Narratives

AN
AnonymousPlanner
ADBE logo
AnonymousPlanner on Adobe ·

Good Value for a Creative Monopoly

Fair Value:US$317.6621.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CO
composite32
RGYAS logo
composite32 on Ronesans Gayrimenkul Yatirim ·

Investing in the future with RGYAS as fair value hits 228.23

Fair Value:₺313.4139.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
JA
Janpeo
RJF logo
Janpeo on Laboratorio Reig Jofre ·

Laboratorio Reig Jofre will experience a revenue boost of 8.51%

Fair Value:€3.2914.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.231.9% undervalued
69 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8590.6% undervalued
89 users have followed this narrative
1 users have commented on this narrative
23 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$561.9326.3% undervalued
1396 users have followed this narrative
2 users have commented on this narrative
12 users have liked this narrative